Surviving morning sickness successfully: from patient's perception to rational management

J Popul Ther Clin Pharmacol. 2014;21(3):e555-64. Epub 2014 Dec 11.

Abstract

Nausea and vomiting of pregnancy (NVP) affects up to 85% of pregnant women, with varying degrees of severity. The most severe form of NVP, known as hyperemesis gravidarum (HG), affects up to 2% of pregnancies. Women who have suffered with severe NVP/HG in a previous pregnancy have a 75-85% recurrence rate. Both patients and physicians often fear the use of pharmacological therapies during pregnancy due to the concerns of potential risks to the fetus. The symptoms and impact of NVP and HG can vary greatly among women, therefore treatment must be tailored to the individual. Updated Motherisk guidelines are presented.

Publication types

  • Review

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Adaptation, Psychological
  • Antiemetics / adverse effects
  • Antiemetics / therapeutic use*
  • Female
  • Fluid Therapy
  • Humans
  • Hyperemesis Gravidarum / psychology
  • Hyperemesis Gravidarum / therapy
  • Morning Sickness / diagnosis
  • Morning Sickness / etiology
  • Morning Sickness / psychology
  • Morning Sickness / therapy*
  • Patients / psychology*
  • Perception*
  • Pregnancy
  • Quality of Life*
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antiemetics